Dutch Biotech Firm Secures Ten Million Euros for Nasal Sprays to Fight Viruses
Leiden, Thursday 25 June 2026
State-backed Invest-NL has invested ten million euros in Dutch biotech Leyden Labs, boosting a forty million euro round to advance clinical trials for virus-blocking nasal sprays.
A Strategic Infusion for Mucosal Protection
The €10 million commitment from the Dutch state-backed impact investor Invest-NL in June 2026 marks a crucial milestone for the Leiden-based biotechnology pioneer Leyden Labs [1]. This strategic investment constitutes a significant portion of a broader €40 million funding round, representing exactly 25% of the total capital raised in this cycle [1]. The capital is earmarked to accelerate the clinical development of Leyden Labs’ innovative mucosal protection platform, which focuses on developing intranasal sprays that offer broad-spectrum protection against a wide array of respiratory pathogens, including seasonal influenza and coronaviruses [1][3].
Global Consortium Backs Mucosal Defence Platform
The funding round highlights a robust international collaboration, drawing capital from a diverse consortium of prominent global impact investors spanning Europe, the United States, and Asia [1][2]. Key participants investing alongside Invest-NL include the European Innovation Council (EIC) Fund, the Gates Foundation Strategic Investment Fund, and ClavystBio [1]. This collective backing materialised shortly after Leyden Labs was selected for the prestigious EIC STEP Scale Up programme, reinforcing the company’s position as a high-potential player in the global life sciences sector [1].
Targeting Viruses at the Point of Entry
The scientific premise of Leyden Labs’ platform lies in shifting the battlefield against respiratory infections to the primary point of entry: the nasal mucosa [1][GPT]. Traditional vaccines are highly effective at generating systemic immunity, but they often allow the virus to establish a foothold in the upper respiratory tract before the immune system can fully respond [GPT]. By delivering broad-spectrum protective antibodies directly into the nasal passages via an easy-to-use spray, Leyden Labs aims to neutralise viruses immediately upon contact, preventing infection and halting transmission before pathogens can replicate and spread [1][GPT].
A Continuous Commitment to National Health Security
This latest financial injection is not an isolated event but a follow-on to previous funding rounds supported by both Invest-NL and the EIC Fund [1]. By continuing to back Leyden Labs, Invest-NL is reinforcing its long-term commitment to nurturing Dutch biotechnology innovations that possess global relevance [1]. The state-backed investor views these nasal sprays not merely as commercial assets, but as critical tools that could significantly bolster national and international resilience against future pandemics and seasonal viral surges [1][GPT].
Leadership Evolution for Clinical Scaling
To steer the company through this intensive clinical-trial phase and eventual commercialisation, Leyden Labs has also strengthened its leadership team [2][GPT]. The biotech firm has appointed the internationally recognised business leader Ben Verwaayen as a new member of its Supervisory Board [2]. Verwaayen’s extensive experience in scaling global enterprises is expected to provide valuable strategic oversight as the company transitions its laboratory breakthroughs into market-ready medical solutions [2][GPT].
De-risking the Lab-to-Market Transition
The journey of a life sciences spin-off from academic research to advanced clinical trials is notoriously capital-intensive and fraught with regulatory hurdles [GPT]. Public-private funding models, such as the one demonstrated by Invest-NL and the EIC Fund, are vital in bridging this developmental gap for biotechnology startups [1][GPT]. By providing early-stage, patient capital, state-backed entities de-risk these complex scientific platforms, thereby making them highly attractive to major international philanthropic and commercial venture funds [1][GPT].
Preventive Medicine Reimagined
Ultimately, the successful deployment of this €40 million round will determine how quickly Leyden Labs can transition its mucosal protection platform from the lab to global markets [1][3]. If the upcoming clinical trials demonstrate the safety and efficacy of these broad-spectrum nasal sprays, it could revolutionise preventive medicine [1][GPT]. Rather than waiting for virus-specific vaccines to be developed and distributed during an outbreak, individuals could soon have access to immediate, localised protection against a broad spectrum of respiratory threats [1][GPT].